04 / RECONSTITUTION
Preparation Protocol — Both Vial Sizes
10MG VIAL
// STANDARD VIAL
10,000 mcg ÷ 300 units = 33.3 mcg/unit
Add 3.0 mL BAC water to 10mg vial.
| DOSE | UNITS | VOLUME |
| LOW500 mcg |
15u |
0.15 mL |
| STD5 mg |
150u |
1.50 mL |
| HIGH10 mg |
300u |
3.00 mL |
30MG VIAL
// BULK VIAL
30,000 mcg ÷ 300 units = 100 mcg/unit
Add 3.0 mL BAC water to 30mg vial.
| DOSE | UNITS | VOLUME |
| LOW500 mcg |
5u |
0.05 mL |
| STD5 mg |
50u |
0.50 mL |
| HIGH10 mg |
100u |
1.00 mL |
Storage: Lyophilized — refrigerate (2–8°C), protect from light. Reconstituted: refrigerate, use within 30 days. Do not freeze reconstituted. The 30mg vial provides approximately 3× more doses per vial at the same price point — preferred for ongoing protocols.
08 / CYCLE PROTOCOL
Recommended Cycle
Active Cycle (Weeks 1–12): 5mg SC daily, fasted mornings or pre-workout. Best results when combined with consistent aerobic and resistance training — MOTS-c amplifies exercise adaptations rather than replacing them. Fat loss, energy improvement, and insulin sensitivity improvements typically apparent within 3–4 weeks.
Longevity Protocol (Ongoing): 5mg SC 3–5×/week indefinitely. This is a maintenance approach to keep MOTS-c at "young" physiological levels. No known long-term toxicity in rodents — considered safe for extended use at research doses.
Power Stack: MOTS-c 5mg + SLU-PP-332 1mg + AOD-9604 300mcg (all pre-workout, SC) = the triple metabolic/exercise-mimetic stack. Hits AMPK, ERR, and growth hormone receptor pathways simultaneously for maximum fat oxidation and mitochondrial upregulation.
Research Compound Notice: MOTS-c has no completed human clinical trials. All efficacy data is from rodent studies or human correlation/epidemiological studies. The compound shows a very favorable preclinical safety profile with no observed adverse effects in rodent longevity studies. Longevity claims are extrapolated from mechanistic and animal data. Not FDA approved. For research purposes.